UCB is partnering with Novartis to co-develop and potentially market UCB0599, a small molecule to inhibit misfolding of the alpha-synuclein protein now in a Phase 2 clinical trial enrolling people with Parkinson’s disease. The agreement also includes an option to co-develop UCB7853 — an antibody against alpha-synuclein —…

Aiming to improve the clinical outcomes of people with Parkinson’s disease, pharmaceutical company UCB is partnering with key U.K. and U.S. nonprofits to establish the Patient Engagement Council for Parkinson’s Research. UCB is teaming up with the Parkinson’s Foundation in the U.S. and Parkinson’s UK in launching…

Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.   UCB’s experimental oral therapy UCB0599 was generally well tolerated in people with mild to moderate Parkinson’s disease…

Neupro patches (rotigotine) — a transdermal form of dopamine treatment — are known to help ease motor symptoms of Parkinson’s disease, and their use can also help with several its non-motor symptoms, researchers report. Their paper, “Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of…

Neupro patches placed on the shin caused significantly less skin irritation and itching in people with Parkinson’s’ disease who previously had site reactions when these transdermal patches were applied elsewhere, a new study has found. The patch’s effectiveness as a…

UCB has announced the start of a Phase 1b clinical trial to evaluate the efficacy and safety of its therapeutic candidate UCB0599 for the treatment of Parkinson’s disease. This multicenter clinical trial will take place across the United States. Current treatments for Parkinson’s, which include…

Neupro patches (rotigotine) have been approved in China for treating symptoms of early-stage idiopathic (of unknown cause) Parkinson’s disease as a stand-alone therapy or in combination with levodopa. Patients may benefit from this treatment strategy over the course of the disease, through to late stages, when levodopa’s benefit wears off or becomes…

Great Lakes NeuroTech (GLNT) announced that it will partner with UCB to develop quantitative tools that will help Parkison’s disease (PD) patients and their clinicians to better assess the impact of  treatment. The goal is to improve patients’ individual experiences as well as, ultimately, improve their quality of life.

Seven large pharmaceutical companies have joined a groundbreaking consortium to accelerate the development of safe and effective therapies for Parkinson’s disease. The Critical Path for Parkinson’s (CPP) Consortium was launched in October 2015 by founders Critical Path Institute (C-Path) and Parkinson’s UK, with a £1 million commitment.